Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Mark Ratner
No NASH treatments are on the market yet, but Phase III data readouts are emerging, mid-stage drugs are demonstrating their capabilities and combinations are in view.
Data science and data analytics offer operational advantages throughout large organizations. And the pharma should approach digital technology pragmatically, first applying the tools to what it already does.
A plethora of clinical studies are showing that new types of data, often captured in the EHR, can help improve the correlation between treatments and outcomes and favorably affect patient care as well as enhance drug development.
If the beginning of 2017 was marked by doubts around whether and how the FDA would act with respect to complex diagnostics, we enter 2018 feeling that slow-moving vessel may finally be turning.
Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.
By taking a different slant on synthetic lethality – the therapeutic process behind AstraZeneca's Lynparza –scientists have identified a potential new drug target for use in prostate cancer, the chromatin helicase DNA-binding factor CHD1.